Salix may be a suitor for Furiex; Rivals chase GSK in asthma;

@FierceBiotech: AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project. More | Follow @FierceBiotech

@JohnCFierce: Upbeat review of failed PhII DMD trial earns Prosensa a big boost to shares. News | Follow @JohnCFierce

@DamianFierce: A quarter of European doctors can't define biosimilars. Story via Bloomberg. | Follow @DamianFierce

@EmilyMFierce: Snails and quails in today's issue of FierceBiotech Research. | Follow @EmilyMFierce

> Salix Pharmaceuticals ($SLXP) could be taking a close look at noted M&A target Furiex Pharmaceuticals ($FURX), Bloomberg reports. News

> GlaxoSmithKline ($GSK) leads the way in the race to cash in on the next generation of asthma treatments, but rivals including Roche ($RHHBY), AstraZeneca ($AZN) and Sanofi ($SNY) are gaining ground. Article

> The rise of biosimilars may be slower than many expect: According to a survey, about 25% of European doctors couldn't define or hadn't heard of copies of biologic treatments. Item

Medical Device News

@FierceMedDev: Teleflex's vascular system gains pivotal FDA clearance--the product comes from a previous M&A deal. More | Follow @FierceMedDev

@MarkHFierce: Mela Sciences' 2013 financials show how tough a relaunch of its skin cancer Dx tool will be. Story | Follow @MarkHFierce

@MichaelGFierce: SynapDx, Broad Institute align to make autism Dx with next-gen sequencing. Item | Follow @MichaelGFierce

@EmilyWFierce: Evidence of world's oldest case of metastatic cancer found in a skeleton in the Sudan. Article | Follow @EmilyWFierce

> OrbiMed backs an Israeli startup developing a futuristic, handheld diagnostic device. News

> St. Jude Medical will test its leadless pacemaker in a massive EU post-marketing trial. Story

> FDA puts the brakes on Avedro with complete response letter on KXL System. More

Pharma News

@FiercePharma: Best-read special report over the weekend: Top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> Pfizer sues India's Torrent in latest bid to fend off generic Viagra. News

> Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales. More

> New incontinence data could give Ipsen's Dysport a path to lucrative urology use. Story

Biotech Research News

> Capturing leukemic stem cells may help propel new drug discovery. More

> Study: Chickens, quails are likely to blame for spread of H7N9. Piece

> Drug derived from snail venom could treat chronic pain with fewer side effects. Article

> Compound stops formation of toxic peptides in mice with Alzheimer's. More

> NIH cuts, sequestration hampering cancer research. Story

> Stem cell therapy improves tendon healing in preclinical study. Item

Pharma Manufacturing News

> Japan's Eisai intends to nearly triple production to 2 billion tablets at its plant in Vizag, India. Report

> The FDA has added two Chinese drug manufacturing facilities to its list of banned plants. Alerts

> India's Supreme Court ruled in favor of a public interest investigation into whether Ranbaxy Laboratories supplied adulterated drugs in the country. Report

> Ranbaxy Laboratories insists the drugs it sells in India are safe and effective. Story

> Optel Visions is expanding its inspection systems offerings. Release

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.